Pro-Dex (PDEX) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
4 Sep, 2025Executive summary
Fiscal 2025 net sales rose 24% year-over-year to $66.6 million, driven by strong demand from the largest customer and successful launch of a next generation handpiece.
Net income for the year reached $9.0 million, up from $2.1 million in fiscal 2024, aided by $1.5 million in unrealized investment gains.
Fourth quarter net sales increased 16% year-over-year to $17.5 million, but gross margin fell to 20% due to unfavorable product mix and higher indirect costs.
Operating income for the year increased 49% to $10.7 million, reflecting higher sales and improved gross profit.
Financial highlights
Gross profit for fiscal 2025 was $19.5 million, up 34% from the prior year; gross margin improved to 29%.
Fourth quarter gross profit declined 15% year-over-year to $3.5 million, with gross margin dropping from 27% to 20%.
Operating expenses for the year rose 20% to $8.8 million, mainly due to increased personnel and R&D costs.
Diluted EPS for fiscal 2025 was $2.67, compared to $0.60 in fiscal 2024.
Cash and cash equivalents at year-end were $419,000, down from $2.6 million the previous year.
Outlook and guidance
Management expects continued revenue and operating income growth in fiscal 2026, supported by a $50.4 million backlog as of June 30.
Initiatives underway to share tariff costs with customers and improve manufacturing systems.
Latest events from Pro-Dex
- Strong sales, new products, and investment gains boosted earnings and cash flow.PDEX
Q2 202629 Jan 2026 - Shareholders to vote on director elections, auditor, executive pay, and equity plan extension.PDEX
Proxy Filing1 Dec 2025 - Shareholders to vote on board elections, auditor ratification, and executive pay amid record growth.PDEX
Proxy Filing1 Dec 2025 - Annual meeting seeks votes on directors, auditor, pay, and equity plan extension.PDEX
Proxy Filing1 Dec 2025 - Director elections, auditor ratification, and say-on-pay vote set for November 21, 2024.PDEX
Proxy Filing1 Dec 2025 - Revenue and net income surged on strong device sales and investment gains, but margin fell.PDEX
Q1 202630 Oct 2025 - Revenue and profit surged on orthopedic product shipments, but inventory controls remain a risk.PDEX
Q2 202516 Oct 2025 - Net income rebounded to $2.5M on 25% sales growth and improved gross margin.PDEX
Q1 202513 Jun 2025 - Sales and operating income rose sharply in 2024, but net income dropped on investment losses.PDEX
Q4 202413 Jun 2025